Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
20 studies found for:    affiris
Show Display Options
Rank Status Study
1 Completed Long-term Safety and Tolerability of AFFITOPE AD01
Condition: Alzheimer's Disease
Intervention:
2 Completed Long-term Safety and Tolerability of AFFITOPE AD02
Condition: Alzheimer's Disease
Intervention:
3 Completed AD01 Follow up Extension Visit
Condition: Alzheimer´s Disease
Intervention:
4 Terminated Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A
Condition: Alzheimer's Disease
Intervention:
5 Terminated Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease
Condition: Alzheimer´s Disease
Intervention:
6 Completed Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Biological: AFFITOPE AD02
7 Completed Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: AFFITOPE AD01;   Biological: AFFITOPE AD01 adjuvanted
8 Active, not recruiting Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects
Condition: Hypercholesterolemia
Interventions: Biological: AFFITOPE® AT04A+adjuvant;   Biological: AFFITOPE® AT06A+adjuvant;   Biological: Adjuvant without active component
9 Active, not recruiting Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA
Conditions: Multiple System Atrophy;   Neurodegenerative Diseases
Interventions: Biological: AFFITOPE® PD01A + Adjuvant;   Biological: AFFITOPE® PD03A + Adjuvant;   Biological: Adjuvant without active component
10 Completed Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease
Conditions: Parkinson Disease;   Neurodegenerative Diseases
Interventions: Biological: Low dose AFFITOPE® PD03A + Adjuvant;   Biological: High dose AFFITOPE® PD03A + Adjuvant;   Biological: Adjuvant without active component
11 Completed Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity
Condition: Parkinson's Disease
Interventions: Biological: AFFITOPE® PD01A;   Other: Control
12 Active, not recruiting Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)
Condition: Parkinson's Disease
Intervention: Biological: AFFITOPE® PD01A
13 Completed Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02
Condition: Alzheimer's Disease
Intervention: Biological: AFFITOPE AD02
14 Completed Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)
Conditions: HDL;   Drug Safety
Intervention: Biological: ATH03
15 Withdrawn Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients
Condition: Parkinson's Disease
Interventions: Biological: AFFITOPE® PD01A + Adjuvant;   Biological: Adjuvant without active component
16 Terminated Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006
Condition: Alzheimer´s Disease
Interventions: Biological: AFFITOPE® AD02;   Biological: Placebo
17 Completed AFF008E: Observational Phase 1b Follow-up Extension Study for Patients With Parkinson's Disease After Immunization With AFFITOPE® PD01A
Condition: Parkinson's Disease
Intervention:
18 Completed Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Biological: AFFITOPE® PD01A;   Other: Control
19 Completed Safety and Tolerability of AFFITOPE AD03
Condition: Alzheimer's Disease
Interventions: Biological: AFFITOPE AD03;   Biological: AFFITOPE AD03 + Alum
20 Completed Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: active: AFFITOPE AD02;   Biological: control: Placebo

Study has passed its completion date and status has not been verified in more than two years.